Neurocrine Biosciences | Gastos De Venta Y Administración



Selling And Administration Expenses Cambio Fecha
AbbVie USD 3.86B 306M 2024-12
Acadia Pharmaceuticals USD 130.08M 3.21M 2024-12
Agios Pharmaceuticals USD 51.7M 13.16M 2024-12
ALKERMES USD 146.99M 3.39M 2024-12
Alnylam Pharmaceuticals USD 295.34M 74.35M 2024-12
Amgen USD 1.88B 253M 2024-12
Biogen USD 677.3M 99.6M 2024-12
BioMarin Pharmaceutical USD 256.77M 46.81M 2024-12
Cytokinetics USD 62.34M 5.69M 2024-12
Dynavax Technologies USD 41.58M 1.48M 2024-12
Exelixis USD 134.33M 22.53M 2025-01
Gilead Sciences USD 1.86B 451M 2024-12
Halozyme Therapeutics USD 42.25M 1.01M 2024-12
Incyte USD 326.71M 17.5M 2024-12
Ionis Pharmaceuticals USD 88.08M 26.44M 2024-12
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Pfizer USD 4.27B 1.06B 2024-12
Prothena USD 16.85M 88K 2024-12
Regeneron Pharmaceuticals USD 792.2M 77.8M 2024-12
Repligen USD 60.32M 13.62M 2024-12
Sarepta Therapeutics USD 163.87M 35.67M 2024-12
Teva Pharmaceutical Industries USD 952M 28M 2024-12
Ultragenyx Pharmaceutical USD 82.49M 2.14M 2024-12
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12



Neurocrine Biosciences Gastos De Venta Y Administración - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Apr 2025.